Comparison of peripheral blood markers in predicting the occurrence of immune-related adverse events in patients with metastatic genitourinary cancer treated with cabozantinib plus nivolumab plus /- ipilimumab

被引：0
|
作者：
Iannantuono, Giovanni Maria
Chandran, Elias
Simon, Nicholas I.
Ley, Lisa
Cordes, Lisa M.
Wang, Tzu-fang
Girardi, Daniel da Motta
Gurram, Sandeep
Valera, Vladimir
Chalfin, Heather
Parnes, Howard L.
Nadal, Rosa
Niglio, Scot Anthony
Boudjadi, Salah
Banday, Abdul Rouf
Kydd, Andre Rashad
Steinberg, Seth M.
Apolo, Andrea B.
机构：
[1] NCI, Genitourinary Malignancies Branch, CCR, NIH, Bethesda, MD USA
[2] Hosp Sirio Libanes, Brasilia, MD, Brazil
[3] NCI, Urol Oncol Branch, CCR, NIH, Bethesda, MD USA
[4] Frederick Hlth Hosp, Frederick, MD USA
[5] NCI, Div Canc Prevent, CCR, NIH, Bethesda, MD USA
[6] NHLBI, Cellular & Mol Therapeut Branch, Lab Transplantat Immunotherapy, NIH, Bethesda, MD USA
[7] NYU, Grossman Sch Med, New York, NY USA
[8] NCI, Biostat & Data Management Sect, OCD, NIH, Bethesda, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16506
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Efficacy of nivolumab in patients treated by corticosteroid due to immune-related adverse events.
    Higashiyama, Ryoko Inaba
    Horinouchi, Hidehito
    Sekine, Katsutoshi
    Matsumoto, Yuji
    Murakami, Shuji
    Goto, Yasushi
    Kanda, Shintaro
    Fujiwara, Yutaka
    Yamamoto, Noboru
    Ohe, Yuichiro
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [42] Eosinophil is a predictor of severe immune-related adverse events induced by ipilimumab plus nivolumab therapy in patients with renal cell carcinoma: a retrospective multicenter cohort study
    Tasaki, Yoshihiko
    Hamamoto, Shuzo
    Yamashita, Shimpei
    Furukawa, Junya
    Fujita, Kazutoshi
    Tomida, Ryotaro
    Miyake, Makito
    Ito, Noriyuki
    Iwamoto, Hideto
    Mimura, Yoshihisa
    Sugiyama, Yosuke
    Unno, Rei
    Okada, Atsushi
    Yasui, Takahiro
    Furukawa-Hibi, Yoko
    FRONTIERS IN IMMUNOLOGY, 2025, 15
  • [43] Real-World Incidence of Immune-Related Adverse Events Associated with Nivolumab Plus Ipilimumab in Patients with Advanced Renal Cell Carcinoma: A Retrospective Observational Study
    Washino, Satoshi
    Takeshita, Hideki
    Inoue, Masaharu
    Kagawa, Makoto
    Soma, Takahiko
    Yamada, Hodaka
    Kageyama, Yukio
    Miyagawa, Tomoaki
    Kawakami, Satoru
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (20)
  • [44] Real world comparison of immune-related adverse events with nivolumab-relatlimab versus ipilimumab-nivolumab in patients with advanced cutaneous melanoma
    Kielkowski, Brooke
    Mansour, Diana
    Ebbert, Brooke
    Seago, Kelsea
    Wen, Sijin
    Li, Hang
    Barrett, Christine
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024,
  • [45] Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors
    Sandigursky, Sabina
    Mor, Adam
    CURRENT RHEUMATOLOGY REPORTS, 2018, 20 (10)
  • [46] Circulating tumor cell (CTC) enumeration in patients (pts) with metastatic genitourinary (mGU) tumors treated in a phase I study of cabozantinib and nivolumab (CaboNivo) plus /- ipilimumab (CaboNivolpi).
    Hu, Zishuo
    Mortazavi, Amir
    Pal, Sumanta K.
    Lara, Primo
    Mayer, Tina M.
    Steinberg, Seth M.
    Mayfield, Christian
    Graap, Katherine
    Mallek, Marissa
    Costello, Rene
    Diaz, Carlos
    Schonhoft, Joseph
    Wang, Yipeng
    Dittamore, Ryan
    Chu, Lincy
    Trepel, Jane B.
    Bottaro, Donald P.
    Apolo, Andrea B.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [47] Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors
    Sabina Sandigursky
    Adam Mor
    Current Rheumatology Reports, 2018, 20
  • [48] Circulating tumor cell (CTC) enumeration in patients (pts) with metastatic genitourinary (mGU) tumors treated in a phase I study of cabozantinib and nivolumab (CaboNivo) plus /- ipilimumab (CaboNivolpi).
    Apolo, Andrea B.
    Mortazavi, Amir
    Hu, Zishuo Ian
    Schonhoft, Joseph
    Chu, Lincy
    Anderson, Amanda K. L.
    Wang, Yipeng
    Dittamore, Ryan
    Pal, Sumanta K.
    Lara, Primo
    Stein, Mark N.
    Steinberg, Seth M.
    Mayfield, Christian
    Cordes, Lisa M.
    Mallek, Marissa
    Costello, Rene
    Diaz, Carlos
    Trepel, Jane B.
    Bottaro, Donald P.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [49] Comparison of Rates of Immune-Related Adverse Events in the Neoadjuvant and Metastatic Settings in Breast Cancer Patients
    Jaboury, Sarah
    Fang, Qing Ze
    Stewart, Josephine
    Barnett, Frances
    Yeo, Belinda
    Jude, Evon
    Grisold, Jasmine
    Devitt, Bianca
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2024, 20 : 42 - 42
  • [50] Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study
    Fink, Morten
    Vittrup, Anders Schwartz
    Bastholt, Lars
    Svane, Inge Marie
    Donia, Marco
    Luczak, Adam A.
    Ruhlmann, Christina H.
    Guldbrandt, Louise Mahncke
    Koehler, Ulrich Heide
    Winther, Mette Lerche
    Ellebaek, Eva
    Haslund, Charlotte Aaquist
    Schmidt, Henrik
    CANCERS, 2021, 13 (21)
12345